Treatment of chronic myelogenous leukemia with interferon alfa-2c: response rate and toxicity in a phase II multicenter study. The Austrian Biological Response Modifier (BRM) Study Group

Semin Hematol. 1993 Jul;30(3 Suppl 3):17-9.
No abstract available

Publication types

  • Clinical Trial
  • Clinical Trial, Phase II
  • Multicenter Study

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Chromosome Aberrations
  • Chromosome Disorders
  • Humans
  • Interferon Type I / adverse effects
  • Interferon Type I / therapeutic use*
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / genetics
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / therapy*
  • Middle Aged
  • Recombinant Proteins

Substances

  • Interferon Type I
  • Recombinant Proteins